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Abstract
Background: Recent reports suggest increase in estrogen receptor (ER), progesterone receptor (PR) negative breast 
cancer yet little is known about histology or receptor status of breast cancer in Indian/Pakistani women.in the U.S.
Methods: We examined the United States National Cancer Institute's Surveillance Epidemiology and End Results 
(SEER) Cancer program to assess: a) frequency of breast cancer by age, b) histologic subtypes, c) receptor status of 
breast cancer and, d) survival in Indians/Pakistanis compared to Caucasians. There were 360,933 breast cancer cases 
diagnosed 1988-2006. Chi-Square analyses and Cox proportional hazards models, to estimate relative risks for breast 
cancer mortality after adjusting for confounders, were performed using Statistical Analysis Software 9.2.
Results: Among Asian Indian/Pakistani breast cancer patients, 16.2% were < 40 yrs. old compared to 6.23% in 
Caucasians (p < 0.0001). Asian Indian women had more invasive ductal carcinoma (69.1 vs. 65.7%, p < 0.0001), 
inflammatory cancer (1.4% vs. 0.8, p < 0.0001) and less invasive lobular carcinoma (4.2% vs. 8.1%, p < 0.0001) than 
Caucasians. Asian Indian/Pakistani women had more ER/PR negative breast cancer (30.6% vs. 21.8%, p = 0.0095) than 
Caucasians. Adjusting for stage at diagnosis, age, tumor grade, nodal status, and histology, Asian Indian/Pakistani 
women's survival was similar to Caucasians, while African Americans' was worse.
Conclusions: Asian Indian/Pakistani women have higher frequency of breast cancer (particularly in age < 40), ER/PR 
negative invasive ductal and inflammatory cancer than Caucasians.
Background
Breast cancer is the most frequently diagnosed cancer in
females in the United States, affecting 1 in 8 women [1].
Worldwide, the incidence of breast cancer varies from
3.9/100,000 in Mozambique to as high as 101.1/100,000
in the U.S [2-5]. Geographic variation in breast cancer
incidence can be attributed to racial and genetic differ-
ences, cultural differences, as well as environmental
exposures that vary throughout the world [5,6]. Recent
profiling work demonstrates that breast cancer is not one
h o m o g e n o u s  d i s e a s e  b u t  c o n s i s t s  o f  a t  l e a s t  5  d i s t i n c t
molecular subtypes with different treatment options and
prognoses [7-12].
Overall incidence of breast cancer is declining in the
United States in the last decade [6,13]. However, the inci-
dence of the biologically aggressive estrogen receptor
(ER) negative, progesterone receptor (PR) negative breast
cancer in women younger than 40 has been increasing in
African Americans in the U.S., Nigerian, Chinese, Viet-
namese, and Taiwanese populations [14-16]. Recent
reports from India and Pakistan suggest an important
increase in the incidence of breast cancer and specifically
ER, PR negative breast cancer among these populations
[16-19]. ER, PR negative breast cancer, of which 50% is
also Her2Neu receptor negative (triple negative), is bio-
logically aggressive, resistant to conventional cytotoxic
chemotherapy treatment, and is associated with reduced
survival compared to other subtypes of breast cancer [20-
23]
Cancer incidence studies in Asian Indians and Paki-
stanis in India and Pakistan as well as emigrants to vari-
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ous countries including Canada, United States,
Singapore, United Kingdom have documented a rise in
breast cancer in premenopausal Indian and Pakistani
women (younger than 40) compared to local Caucasian
women [24-33]. Yet very little is known about the specific
histologic subtypes or receptor status of breast cancer in
women of Indian/Pakistani origin in the U.S. [34-38].
Understanding frequency of occurrence of specific breast
cancer subtypes and associated risk factors in Indians/
Pakistanis may elucidate breast cancer prevention,
screening and treatment strategies tailored to the unique
risk of this ethnic group.
We, therefore, explored whether analysis of United
States National Cancer Institute's Surveillance Epidemi-
ology and End Results (SEER) Program would: a) indicate
a disproportionately high frequency of occurrence of
breast cancer in Asian Indian/Pakistani women younger
than 40 yrs (premenopausal age) compared to Caucasian
females, b) provide data on specific histologic subtypes of
breast cancer (eg. invasive ductal, inflammatory or lobu-
lar carcinoma), and c) molecular subtypes of breast can-
c e r  b y  r e c e p t o r  s t a t u s  i n  A s i a n  I n d i a n  a n d  P a k i s t a n i
women in the United States and, 4) the impact of these
subtypes on breast cancer specific survival. In this explor-
atory analysis, we examined demographic characteristics
such as age and marital status and biological variables
such as histology, estrogen and progesterone receptor
status and in situ versus invasive disease as predictive
variables for disease outcome and survival.
Methods
Subjects were 360,933 females, identified as Caucasian,
African American, Hispanic or Indian/Pakistani, diag-
nosed with breast cancer between 1988 and 2006. Infor-
mation regarding these subjects was obtained from the
population-based SEER database in a case listing session.
The SEER program collects information about all inci-
dent cancer cases including patient demographics, tumor
site, stage at diagnosis, first course of treatment and
annual follow up for vital status (SEER website: http://
seer.cancer.gov/about/). Currently, 18 population-based
r e g i s t r i e s  c o v e r  2 6 %  o f  t h e  U n i t e d  S t a t e s  p o p u l a t i o n .
Overall, the combined registries are comparable to the
rest of the United States population with regard to pov-
erty and education levels, but are slightly more urban and
contain a higher proportion of foreign-born individuals.
For the purposes of this analysis, data from 6 SEER sites
with high proportion of Indian/Pakistani women were
used. These 6 sites are: Atlanta--Georgia, Connecticut,
California (Los Angeles, San Francisco-Oakland, San
Jose-Monterey, and greater California), Metropolitan
Detroit--Michigan, New Jersey, and Seattle-Puget Sound-
-Washington. In the SEER database, histological type of
tumor is coded using International Classification of Dis-
eases for Oncology, Third Edition (ICD-O) codes. The
corresponding ICD-O morphology codes for breast can-
cers (Site and Morphology code = 'Breast') were selected:
8530 (inflammatory), 8522-8524 (mixed), 8100, 8500,
8501, 8503, 8521 and 8523 (ductal), and 8520 (lobular).
Two behavior codes were also selected: 2 (in situ) and 3
(invasive). For the purposes of this analysis, a categorical
variable was created, with categories for each histological
type and behavior. Variables of interest included age at
diagnosis, marital status, registry site, AJCC stage, tumor
markers (ER and PR), vital status and survival time
(months). Population denominators were not available
for the Indian/Pakistani population in SEER or in United
States Census data, so these results represent frequen-
cies, not rates. As these data are de-identified, human
investigation approval was not necessary for this project,
but all investigators have signed limited-use data agree-
ments to access and analyze SEER data.
Statistical Methods
Bivariate analyses (PROC FREQ) and multinomial analy-
ses (PROC CATMOD) were implemented using Statisti-
cal Analysis Software (SAS) version 9.2. The p-values
presented represent comparisons between Caucasian and
Indian/Pakistani breast cancer patients. Bivariate analy-
ses compared categorical age at diagnosis, marital status
and SEER program site by race. Multinomial analyses
compared clinical characteristics (histology, AJCC SEER
modified stage, grade, ER/PR status, tumor size and
nodal status) by race adjusting for age and SEER program
site. For age, we assigned three age categories: age < 40
yrs corresponding to premenopausal, age 40-50 yrs. for
perimenopausal and age > 50 for post menopausal age
groups. These are empirical groupings and not based
upon hormone testing to establish menopausal status.
Tumor size was categorized as < 1 cm, 1 - 4 cm and > 4
cm.
Hormone Receptor Status Analysis
Estrogen receptor was available for 50.5% and progester-
one receptor status was available for 49.8% of all breast
cancer cases, including in situ ductal or lobular carci-
noma (n = 204), invasive ductal (n = 817), invasive lobular
(n = 50) and inflammatory breast cancer (n = 16) in Asian
Indian/Pakistani females (n = 1087). The proportion of
missing data did not differ between Caucasian, Indian/
Pakistani, Hispanic and African-American breast cancer
patients.
Survival
Data from all 6 SEER registries were used for survival
analyses. We chose to analyze from 1988 forward because
prior to 1988 Asian Indians and Pakistanis were identi-
fied only as "Other Asians". Cox proportional hazards
models were used to estimate relative risks (RRs) and 95%Kakarala et al. BMC Cancer 2010, 10:191
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Confidence Intervals for mortality from breast cancer
after adjusting for relevant confounders including AJCC
SEER modified stage, histology, behavior, age at diagnosis
and SEER program site. A minimum survival time of 2
months was used in selecting cases in order to exclude
those diagnosed only at autopsy or those who may have
d i e d  b e f o r e  p u r s u i n g  t r e a t m e n t .  N o n  H i s p a n i c  C a u c a -
sians served as the reference group for relative risk com-
parisons. All tests were two tailed and p values < 0.05
were considered statistically significant.
Results
Frequency of Breast Cancer in Asian Indians/Pakistanis
A total of 1350 cases of breast cancer cases among Asian
Indian/Pakistani women were found in the SEER data-
base from 6 SEER sites between 1988-2006. Among Asian
Indian/Pakistani breast cancer patients, 16.2% were
women younger than age 40 or premenopausal women
compared to 6.23% in Caucasian women (p < 0.0001) and
10.8% of African American and 11% of Hispanic women
as shown in T able 1. This higher percentage of women
under age 40 with breast cancer diagnoses in Asian Indi-
ans/Pakistanis was also found in the perimenopausal 40-
50 yr olds as well with 29.9% of Asian Indians/Pakistanis
compared to 18.9% of Caucasian women (p < 0.0001).
African American and Hispanic women between ages 40-
50 had intermediate frequency with 23.1% and 24.6%
respectively. A correspondingly lower percentage of
breast cancer was found in postmenopausal (age > 50
yrs.) Asian Indian/Pakistani women compared to Cauca-
sians (53.9% vs. 75.5%, p < 0.0001).
Breast Cancer Stage at Diagnosis in Asian Indians/
Pakistanis
Percentage of women diagnosed with stage IV or meta-
static disease was similar in Asian Indians/Pakistanis
compared to Caucasians (4.9 vs. 4.5%). African American
and Hispanic women had significantly higher percentage
of women presenting with stage III (11.9% and 9.6% ver-
sus 7.0%, p < 0.01) compared to Caucasian women. Afri-
can American women also had the highest percent of
Table 1: Age at diagnosis, marital status and survival of women with breast cancer, 6 SEER program sites, 1988-2006, by 
ethnicity
Variable Caucasian
n = 300,494
Indian/Pakistani
n = 1,350
African-American
n = 40,647
Hispanic
n = 18,442
P value*
Age category < 0.0001
Premenopausal (age < 40) 18001 (6.0) 219 (16.2) 4405 (10.8) 2026 (11.0)
Perimenopausal (age 40-50) 55597 (18.5) 403 (29.9) 9401 (23.1) 4536 (24.6)
Postmenopausal (age > 50) 226896 (75.5) 728 (53.9) 26841 (66.0) 11880 (64.4)
Marital Status < 0.0001
Single 33145 (11.0) 92 (6.8) 9528 (23.4) 3080 (16.7)
Married 166927 (55.6) 1005 (74.4) 14537 (35.8) 9814 (53.2)
Other 100422 (33.4) 253 (18.7) 16582 (40.8) 5548 (30.1)
SEER Program Site < 0.0001
San Franciso-Oakland 44281 (14.7) 312 (23.1) 5129 (12.6) 3392 (18.4)
Connecticut 53693 (17.9) 136 (10.1) 3293 (8.1) 1743 (9.5)
Metropolitan Detroit 49462 (16.5) 141 (10.4) 12416 (30.6) 466 (2.5)
Seattle (Puget Sound) 54259 (18.1) 84 (6.2) 1378 (3.4) 476 (2.6)
Metropolitan Atlanta 23223 (7.7) 131 (9.7) 8547 (21.0) 467 (2.5)
San Jose-Monterey 18291 (6.1) 238 (17.6) 412 (1.0) 1679 (9.1)
Los Angeles 57285 (19.1) 308 (22.8) 9472 (23.3) 10219 (55.4)
Mean Survival in Months (SD) 67.0 (53.7) 48.0 (46.2) 53.0 (52.7) 56.0 (49.5) < 0.0001**
*p < 0.0001 for difference between Asian Indian/Pakistani women and Caucasian women.
Survival analysis here is univariate by ethnicity. Multivariate analysis including histologic, molecular and other disease and patient variables 
is presented in the results text.
**Wilcoxon rank-sum test between Indian/Pakistani and Caucasian median survivalKakarala et al. BMC Cancer 2010, 10:191
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stage IV disease (8.1% compared to 4.5% in Caucasians, p
< 0.01).
Breast Cancer Histology and Receptor Status in Asian 
Indians/Pakistanis
The histologic subtypes of in situ lobular or mixed in situ
cancer differed significantly between Asian Indian/Paki-
stani compared to Caucasian women, while in situ ductal
cancer did not differ significantly as shown in Table 2 (p =
0.02), however, given the large number of subjects the sig-
nificance is not likely meaningful. Asian Indian women
had a slightly higher frequency of invasive ductal carci-
noma (69.1 vs. 65.6%, p < 0.0001) and lower invasive lob-
ular carcinoma (4.2% vs. 8.2%, p < 0.0001) compared to
Caucasian women. Mixed histology tumors were of simi-
lar frequency of occurrence in both ethnic groups.
Inflammatory breast cancer, which is a particularly
aggressive subtype, was slightly higher in Asian Indian/
Pakistanis, African Americans and Hispanics compared
to Caucasians (1.4%, 1.5%, 1.6% respectively vs. 0.8%, p <
0.0001). More Asian Indian/Pakistani women were diag-
nosed at AJCC Seer Modified Stage II (47.5% vs. 37.5%, p
< 0.001), III (11.3% vs. 7.0%, p < 0.001) and a smaller per-
centage in stage I (36.3% vs. 51.0%, p < 0.001) compared
to Caucasian women as shown in Table 3. There was
higher percentage of estrogen and progesterone receptor
negative breast cancer (30.6% vs. 21.8%, p = 0.0095)
breast cancer in Asian Indian/Pakistani women com-
pared to Caucasians (Table 2). Hispanics were similar to
Asian Indians/Pakistanis in receptor negativity (29.7 vs.
30.6%) but African Americans had the highest percentage
of ER/PR negative disease 41% compared to 21.8% in
Caucasians (p < 0.0095). We explored marital status of
breast cancer patients and found that a significantly
greater percentage of Asian Indian/Pakistani than Cauca-
sian breast cancer patients are married (74.4% vs. 55.4%,
p < 0.0001).
Breast Cancer Specific Survival in Asian Indians/Pakistanis
In order to better understand the correlates of survival in
racial subgroups, we further examined this survival out-
come in multivariate regression analysis using age at
Table 2: Histology and receptor status of breast cancer in women in the 6 SEER program sites diagnosed between 1988-
2006 by ethnicity
Variable Caucasian Indian/Pakistani African-American Hispanic P value*
Histology 0.02*
In situ---Ductal 31998 (12.1) 142 (12.0) 4409 (12.7) 1907 (11.8)
In situ---Lobular 6641 (2.5) 21 (1.8)* 648 (1.9) 330 (2.0)
In situ--Mixed 6243 (2.4) 41 (3.5)* 984 (2.8)4 2 0  ( 2 . 6 )
Histology < 0.0001*
Invasive--Ductal 173174 (65.6) 817 (69.1)* 24254 (69.6) 10858 (67.3)
Invasive---Lobular 21725 (8.2) 50 (4.2)* 1752 (5.0) 1023 (6.3)
Invasive--Mixed 21853 (8.3) 96 (8.1) 2253 (6.5) 1322 (8.2)
Inflammatory carcinoma 2218 (0.8) 16 (1.4)* 537 (1.5) 265 (1.6)
Estrogen Receptor (ER) 0.0688*
Positive 130267(79.3) 463 (71.9)* 12902 (62.6) 6984 (72.3)
Negative 34040 (20.8) 181 (28.1)* 7724 (37.5) 2673 (27.7)
Progesterone Receptor (PR) 0.0260*
Positive 108451(68.2) 391 (62.2)* 10548 (53.1) 5758 (62.5)
Negative 50533 (31.8) 238 (37.8)* 9315 (46.9) 3449 (37.5)
ER/PR 0.0095*
Positive/Positive 103767 (78.2) 377 (69.4)* 9702 (58.9) 5408 (70.3)
Negative/Negative 28994 (21.8) 166 (30.6)* 6772 (41.1) 2285 (29.7)
* p value is for comparison between Asian Indian/Pakistani and Caucasian women adjusted for age at diagnosis and SEER programKakarala et al. BMC Cancer 2010, 10:191
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diagnosis, AJCC SEER Modified Stage, and histologic
subtype as predictors for survival (Table 4). Survival time
was censored at five years. Estrogen/progesterone recep-
tor status and nodal status were not used as their data
were sparse in the younger age groups in minority popu-
lations. Women with inflammatory breast cancer were
found to have a hazard ratio (HR) of 3.47 (CI: 2.48 - 4.86),
increasing stage HR of 2.80 (CI: 2.63-2.98), African
Americans HR of 1.59 (CI: 1.37-1.85), and older age
group at diagnosis a HR of 2.0 (CI: 1.75-2.29) of not sur-
viving to 5 years post diagnosis compared to Caucasian
women. Once stage at diagnosis, age, and histologic pro-
file were controlled for, the survival outcome of Asian
Indian/Pakistani women did not differ significantly from
Caucasians (HR = 0.45, C.I. = 0.11 - 1.79) however, Afri-
can American women had significantly worse survival
than Caucasians.
Discussion
Asian Indians/Pakistanis are one of the fastest growing
ethnic groups in the United States and have a higher fre-
quency of breast cancer than Caucasians [26,33]. Our
analysis of breast cancer diagnoses using the SEER data-
base for cases diagnosed from 1988-2006 finds a dispro-
p o r t i o n a t e l y  h i g h  o c c u r r e n c e  r a t e  o f  b r e a s t  c a n c e r  i n
Asian Indian/Pakistani women younger than 40 yrs. com-
pared to Caucasians. It is possible the overall age distri-
bution of Asian Indian/Pakistani women is younger
compared to the other racial/ethnic groups in the United
States, resulting in a disproportionate breakdown by age.
This could be due to immigration patterns, as the Indian
population reflects the rapid increases in young immi-
grants in the latter half of the 20th century. Unfortunately,
immigration data were not available in SEER, but our
results suggest the need for future studies to address this
question. However, these findings are consistent with
similar high rates observed among south Asians or Indi-
ans in Singapore, United Kingdom, Malaysia, Canada and
in Indians in India [25,26,33,34,39-41]. We were unable to
examine trends over time using the SEER program due to
the relatively small number of cases diagnosed every year
for Asian Indians and Pakistanis, however at least one
Table 3: Stage at diagnosis, tumor grade, primary tumor size and nodal status by ethnicity in 6 SEER program sites 
between 1988-2006.*
Variable Caucasian Indian/Pakistani African-American Hispanic P value*
AJCC stage < 0.001
Stage I 118856 (51.0) 381 (36.3)* 11187 (35.9) 6069 (41.9)
Stage II 87267 (37.5) 499 (47.5)* 13735 (44.1) 6322 (43.7)
Stage III 16236 (7.0) 119 (11.3)* 3698 (11.9) 1394 (9.6)
Stage IV 10619 (4.5) 51 (4.9) 2512 (8.1) 694 (4.8)
Tumor Grade < 0.0001
1 42232 (19.0) 150 (13.5)* 3751 (12.5) 2191 (15.0)
2 93718 (42.2) 452 (40.8) 10376 (34.6) 5751 (39.5)
3 76391 (34.4) 465 (41.9)* 14561 (48.6) 5856 (40.2)
4 9607 (4.3) 42 (3.8) 1254 (4.2) 758 (5.2)
Primary Tumor Size 0.4432
< 1 cm 8364 (25.4) 51 (21.4) 938 (18.2) 564 (20.5)
1 -- 4 cm 20748 (62.9) 151 (63.5) 3140 (60.9) 1758 (64.0)
> 4 cm 3887 (11.7) 36 (15.1) 1079 (20.9) 425 (15.5)
# of nodes positive 0.4668
0 144518 (68.6) 597 (59.5) 16291 (60.4) 8459 (63.1)
1-3 42546 (20.2) 236 (23.5) 6474 (24.0) 2979 (22.2)
4-9 15256 (7.2) 111 (11.1) 2708 (10.1) 1242 (9.3)
> 9 8325 (4.0) 60 (5.9) 1481 (5.5) 718 (5.4)
* p value is for comparison between Asian Indian/Pakistani and Caucasian women adjusted for age at diagnosis and SEER programKakarala et al. BMC Cancer 2010, 10:191
http://www.biomedcentral.com/1471-2407/10/191
Page 6 of 8
study shows a rise in breast cancer incidence rates in
Asian Indians over time [14].
Over the past decade, the biology of breast cancer has
been redefined into groups of distinct biological sub-
types. Each subtype presents with specific clinical, patho-
logical and molecular phenotypes associated with diverse
natural histories, therapeutic implications and prognoses
[8,42-47]. Previously published studies of breast cancer in
Asian Indians did not examine the frequency of specific
histologic subtypes of breast cancer: invasive ductal, lob-
ular and inflammatory carcinoma of the breast. Each of
these subtypes has a different biologic behavior and prog-
nosis [11,48,49]. Inflammatory breast cancer, for exam-
ple, is the most aggressive histologic subtype with worse
hazard ratio for 5 year survival in our own multivariate
analysis [50-52] and occurs more frequently among Asian
Indians compared to Caucasians in our analysis. Lobular
invasive carcinoma may present with bilateral disease and
recur many years from primary disease presentation. The
most common histology in both Caucasians and Asian
Indians/Pakistanis, invasive ductal carcinoma is usually
unilateral and risk of recurrence decreases as time elapses
from primary diagnosis [49,53,54]. Differences in behav-
ior of distinct breast cancer histologies determine
whether a patient receives breast conservation or aggres-
sive surgical treatment, sentinel node or complete axillary
dissection. Systemic treatment such as duration of hor-
mone therapy, targeted therapy for Her2Neu positive dis-
ease and followup patterns also differ for different breast
cancer subtypes [55]. Our SEER analysis shows that inva-
sive ductal carcinoma is more frequently diagnosed in
Asian Indian/Pakistani women compared to Caucasian
women while diagnosis of lobular carcinoma is corre-
spondingly lower.
A higher proportion of breast cancer in Asian Indian/
Pakistani women compared to Caucasians (30.6% vs.
21.8%, p < 0.0095) in the SEER database was ER and PR
negative. It must be noted that individuals for whom
receptor status was missing were excluded from that
analysis and missing data was comparable in both groups.
Reports in Asian Indians in India and the United King-
dom also document high rates of ER, PR negative breast
cancer [34,36]. Interestingly, when receptor status was
examined by age, we found that this difference was driven
by increased percentage of ER/PR negative disease in 40-
50 yr olds and those older than 50, rather than by younger
aged women.
We were unable to examine Her2 Neu receptor status
as this variable is only recently being collected by the
SEER program. However, pathologic assessments of
tumors over time have found the particularly aggressive,
and least treatable, triple negative (ER, PR and Her2Neu
negative) or basal breast cancer molecular subtype to be
common in Asian Indians [38,56]. This subtype of breast
cancer is more common among BRCA1 gene mutation
carriers, however, known BRCA1 and BRCA2 mutations
Table 4: Disease-specific five- year survival using Cox-proportional hazards adjusted for SEER site
Predictor Univariate HR (95% C.I.) Multivariate model
Stage 3.08 (2.905 -- 3.26) 2.80 (2.63 -- 2.98)
Inflammatory 5.41 (5.12 -- 5.71) 3.47 (2.48 -- 4.86)
Mixed 0.73 (0.70 -- 0.77) 0.95 (0.70 -- 1.28)
Ductal 1.03 (1.00 -- 1.06) 1.43 (1.13 -- 1.80)
Lobular 1.00 (reference) 1.00 (reference)
African-American 1.66 (1.62 -- 1.69) 1.59 (1.37 -- 1.85)
Hispanic 0.95 (0.91 -- 0.99) 0.72 (0.52 -- 0.98)
Indian/Pakistani 0.82 (0.70 -- 0.96) 0.45 (0.11 -- 1.79)
Caucasian 1.00 (reference) 1.00 (reference)
Age group 1.39 (1.37 -- 1.41) 2.00 (1.75 -- 2.29)Kakarala et al. BMC Cancer 2010, 10:191
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do not seem to explain the triple negative cancer in
Indian women [57-59]. Stage at diagnosis is critical in
breast cancer as early stage cancer is curable while more
advanced stages are not [28,60]. Asian Indian/Pakistani
women were diagnosed at significantly more advanced
stages of breast cancer than Caucasian women suggesting
a need to raise awareness of screening recommendations
in this ethnic group
Conclusion
In conclusion, Asian Indian and Pakistani women in the
US had more ER and PR negative tumors than their Cau-
casian counterparts. Invasive ductal carcinoma is the
most common histology. Inflammatory cancer is also
more common in Asian Indians/Pakistanis than Cauca-
sians. Given the limited treatment options for receptor
negative breast cancer and poor prognosis, it is important
to encourage screening and early diagnosis measures
such as annual clinical breast exams for these women.
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